-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 13, UCB announced that it had received the FDA's Complete Response Letter (CRL) for the marketing application of bimekizumab in the treatment of moderate to severe plaque psorias.
bimekizumab was approved in the EU and UK in August 2021 for adults with moderate-to-severe plaque psoriasis suitable for systemic therapy and in Japan in January 2022 for the treatment of plaque in adults who have not responded adequately to existing therapies psoriasis, generalized pustular psoriasis, and erythrodermic psorias.
bimekizumab is a humanized IgG1 mAb that binds to similar sites of IL-17A and IL-17F, while inhibiting IL-17A and IL-17F, a unique mechanism of action compared to other anti-IL-17A Drugs may have better effica.
The current global IL-17 drug market size is nearly 7 billion US dollars, and Novartis Cosentyx (secukinumab) accounts for nearly 60%, about 4 billion US dolla.
